Verecor reports Phase 3 migraine-prevention results: 1.3 fewer monthly migraine days than placebo
The event
Verecor Therapeutics published topline Phase 3 results on July 7 for its migraine-prevention drug velartinib: across 1,204 participants over 12 weeks, the treatment group averaged 4.2 fewer monthly migraine days versus 2.9 for placebo, a difference of 1.3 days.
The record
Confirmed3
Independently corroborated by multiple sources.
Verecor published topline results on July 7 from a Phase 3 trial of 1,204 participants with chronic migraine, run over 12 weeks at 61 sites.
4 sourcesNational WireJul 7, 2026The Morning StandardJul 7, 2026The Civic PostJul 8, 2026Broadcast One NewsJul 7, 2026The treatment group averaged 4.2 fewer monthly migraine days from baseline, versus 2.9 for placebo — a placebo-adjusted difference of 1.3 days (p < 0.001).
Discontinuation due to adverse events was 6.1 percent in the treatment group versus 4.8 percent for placebo; the most commonly reported events were nausea and dizziness.
Attributed1
Stated by a party involved. Reported, not verified.
The company plans a regulatory submission in the fourth quarter of 2026.
Said by: Verecor Therapeutics
1 sourceNational WireJul 7, 2026
Disputed1
Credible sources contradict one another. Both positions shown.
Whether a 1.3-day placebo-adjusted improvement is clinically meaningful.
Verecor Therapeutics
The result is meaningful for patients who have failed at least two prior preventives, a subgroup that showed a 2.1-day placebo-adjusted improvement.
University headache researchers not involved in the trial
The overall difference falls below the 1.5-day threshold that many headache specialists use as the minimum clinically important difference, and the subgroup finding was not a pre-registered primary endpoint.
What is not known
Unknown2
An open question. Listed, not papered over.
Planned pricing; the company has not commented.
When the full peer-reviewed dataset will be published. Topline results are company-reported.
Coverage lens4 outlets
Headlines reproduced verbatim from each outlet, side by side. Same event; the contrast is the point. The Ledger adds no commentary.
- National WireJul 7, 2026
Verecor migraine drug beats placebo in Phase 3 trial; company plans regulatory filing
- The Morning StandardJul 7, 2026
New migraine drug shows modest benefit over placebo in large trial
- The Civic PostJul 8, 2026
A new migraine pill works. Is 1.3 days a month enough?
- Broadcast One NewsJul 7, 2026
BREAKTHROUGH HOPE for millions of migraine sufferers